NCT04189757 2026-04-16
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT04978584 2026-04-15
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06651970 2026-04-15
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
NCT07277231 2026-04-15
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT04169737 2026-04-14
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04560322 2026-04-13
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
Phase 2 Recruiting
NCT06136559 2026-04-13
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06564038 2026-04-13
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT06428019 2026-04-09
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT07029737 2026-04-08
SOUND-MCL
AstraZeneca
Phase 2 Recruiting
NCT04002947 2026-04-06
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04646395 2026-04-06
Study of Acalabrutinib and Tafasitamab in MZL Patients
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT04722172 2026-04-06
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT02477696 2026-03-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02586857 2026-03-25
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT02717611 2026-03-25
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Acerta Pharma BV
Phase 2 Active not recruiting
NCT05388006 2026-03-25
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT04115631 2026-03-23
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02180724 2026-03-20
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Acerta Pharma BV
Phase 2 Active not recruiting